Introduction Depression often co-occurs with chronic back pain (CBP). Internet and mobile-based interventions (IMIs) might be a promising approach for effectively treating depression in this patient group. In the present study, we will evaluate the effectiveness and cost-effectiveness of a guided depression IMI for individuals with CBP (eSano BackCare-D) integrated into orthopaedic healthcare.
Methods and analysis In this multicentre randomised controlled trial of parallel design, the groups eSano BackCare-D versus treatment as usual will be compared. 210 participants with CBP and diagnosed depression will be recruited subsequent to orthopaedic rehabilitation care. Assessments will be conducted prior to randomisation and 9 weeks (post-treatment) and 6 months after randomisation. The primary outcome is depression severity (Hamilton Rating Scale for Depression-17). Secondary outcomes are depression remission and response, health-related quality of life, pain intensity, pain-related disability, self-efficacy and work capacity. Demographic and medical variables as well as internet affinity, intervention adherence, intervention satisfaction and negative effects will also be assessed. Data will be analysed on an intention-to-treat basis with additional per-protocol analyses. Moreover, a cost-effectiveness and cost-utility analysis will be conducted from a societal perspective after 6 months.
Ethics and dissemination All procedures are approved by the ethics committee of the Albert-Ludwigs-University of Freiburg and the data security committee of the German Pension Insurance (Deutsche Rentenversicherung). The results will be published in peer-reviewed journals and presented on international conferences.
Trial registration number DRKS00009272; Pre-results.
- chronic back pain
- health care services research
- randomized controlled trial
- study protocol
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
- chronic back pain
- health care services research
- randomized controlled trial
- study protocol
Strengths and limitations of this study
This is a protocol for the first large-scale, multicentre randomised controlled trial examining the effectiveness of a depression internet and mobile-based intervention (IMI) for individuals with chronic back pain (CBP) and depression.
This is the first trial examining the cost-effectiveness of a depression IMI for individuals with CBP and depression.
The IMI will be implemented as integrated part of routine orthopaedic healthcare, thus overcoming the self-referral bias of most prior IMI trials, examining the possibility to improve patients' medical sector transitions by means of an e-mental-health offer.
We use standardised interviews for the diagnosis and clinical rating scales for the assessment of the severity level of depression (Structured Clinical Interview and Hamilton Rating Scale for Depression/Quick Inventory of Depressive Symptomatology).
Findings will be limited to patients with back pain and depression receiving a depression IMI as aftercare intervention of a biopsychosocial focused orthopaedic inpatient treatment, which might limit the (incremental) effectiveness of the intervention.
The two widespread conditions chronic back pain (CBP) and depression belong to the top 10 causes of years lived with disability worldwide.1 The global 1-month adult prevalence for low back pain is estimated to be 23.2% and a substantial increase during the next decades can be expected.2 Depression has been shown to be the leading cause of burden of diseases in middle-income to high-income countries with a lifetime prevalence of about 14.6% in high-income countries.3 A strong association between depression and CBP has been frequently reported with prevalence rates for depression ranging from 21% to 50% in back pain and chronic low back pain individuals.4 Several systematic reviews highlight a significant prognostic association between comorbid depression and increased morbidity of different somatic conditions and healthcare costs as well as diminished quality of life.5–7 Moreover, depression is one of the core predictors of persistent pain symptoms, increased pain-related disability and poor treatment outcomes in pain patients.4 8 9
There is evidence for the efficacy of psychological interventions for chronic pain10 and also for chronic low back pain in specific 11 aiming at pain intensity or disability/interference as primary outcomes. To the best of our knowledge however, there is no study that has examined the effects of psychological depression interventions in the population of CBP focussing on depression as the primary outcome.12 Indeed, the evidence on depression treatments for patients with chronic pain and clinical depression is very limited, mostly relying on a few collaborative/stepped care trials conducted in the last two decades.13–15
In order to improve healthcare for CBP individuals, internet and mobile-based interventions (IMIs) are considered to be a promising approach.16 17 Among numerous meta-analyses highlighting the efficacy of IMIs with regard to the reduction of depressive symptoms,18–21 one meta-analysis quantified the superiority of online depression interventions over waiting-list and treatment as usual (TAU) with standardised mean differences of d=−0.68 (95% CI −0.85 to −0.52; n=8) and d=−0.39 (95% CI −0.66 to −0.12; n=8),20 although effect moderating factors of IMIs remain unclear.22 As most trials used highly selective recruitment strategies, the evidence for the effectiveness of IMIs for depression (ie, performance of an intervention when implemented within typical clinical practice, investigated by means of pragmatic trials) is far less conclusive23 and many health systems have not included IMIs as an integrated treatment component. As an implemented part of a comprehensive care system, IMIs could reduce the deficiencies of most current healthcare systems in coordinating transitions of care, such as the transition from the inpatient to outpatient setting, where recommendations are regularly lost in transition.24–26
The present WARD-BP study (web-based aftercare depression intervention following rehabilitation for individuals with depression and chronic back pain) aims to investigate the effectiveness and cost-effectiveness of the depression IMI ‘eSano BackCare-D’ in a study population of CBP with diagnosed depression in the aftermath of orthopaedic rehabilitation care. The primary research question is:
Is eSano BackCare-D effective in reducing depression in individuals with CBP and diagnosed depression compared to TAU?
Secondary research questions are:
Is eSano BackCare-D effective with regard to depression remission and response, health-related quality of life, pain intensity, pain-related disability, self-efficacy and work capacity in individuals with CBP and diagnosed depression compared to TAU?
Is eSano BackCare-D cost-effective in individuals with CBP and diagnosed depression compared to TAU from a societal perspective?
Which factors moderate and mediate the effects of eSano BackCare-D?
Methods and analysis
WARD-BP is a multicentre pragmatic randomised controlled clinical trial (RCT) of parallel design. All participants receive TAU. We conduct assessments in both groups before randomisation (T0), 9 weeks (T1=post-treatment in case of regular IMI use) and 6 months (T2) after randomisation. Trial participants receive €15 per completed post-telephone and follow-up telephone assessment, see figure 1 for study flow.
Randomisation and allocation of participants to the two groups (intervention or TAU) was prepared in advance by an independent researcher (SaS) by means of a web-based programme (https://www.sealedenvelope.com/) using permuted block randomisation with variable block sizes of 4, 6, 8 (randomly arranged), ratio of 1:1. Participants are stratified by centre. Centres are all eight orthopaedic clinics where recruitment is conducted personally and a ninth (meta-)clinic, which includes all participants recruited by letter (see recruitment). The independent researcher (SaS) is responsible for the allocation of participants to trial arms as well as the administration of the trial and is blinded to the treatment process and assessment of the participants.
Recruitment has started in October 2015 and is planned to end in July 2017. While this study protocol has been submitted for publication after start of recruitment (due to usual writing-up, commenting and approving procedures by all coauthors), clinical trial registry took place prior to recruitment start.
Using the Patient Health Questionnaire (PHQ-927), we conduct two consecutive depression screenings within 2–3 weeks. In case of only one positive screening (PHQ ≥5), a third PHQ will be administered 2 months later via telephone interview. We recruit potential participants in orthopaedic rehabilitation units in Germany with two different recruitment strategies.
In the first recruitment setting (personal recruitment), patients with two positive screenings receive information on the intervention by clinic staff during their orthopaedic care. Patients providing their informed consent to the clinical trial study team (exemplary informed consent form, see online supplementary material) are contacted by the study team in order to clarify further eligibility criteria by means of an online and telephone assessment including a telephone administered clinical interview. The participating clinics are compensated for their recruitment efforts (ie, selection of back pain patients, screening procedure, informed consent, documentation according to CONSORT28–30, providing access to medical records) with €320 per randomised participant. The second recruitment strategy (recruitment by letter) involves a letter with information flyers and description of study process for back pain patients after discharge from orthopaedic rehabilitation units across Germany with a link to fill out an online PHQ-screening. Individuals screened positive and providing informed consent are contacted for the second PHQ-screening and a clinical interview via telephone equivalent to the first recruitment strategy.
Supplementary file 1
We include patients if they fulfil the following inclusion criteria:
aged 18 years or older;
CBP for at least 6 months assessed by physician;
mild-to-moderate depression or dysthymia according to the Structured Clinical Interview (SCID 31 32) during telephone interview;
sufficient knowledge of German language;
internet and PC access.
Patients are excluded in case of:
receiving ongoing psychotherapy or beginning psychotherapy within the next 3 months,
being currently suicidal or reporting suicidal attempts in the past 5 years assessed during telephone interview;
a current diagnosis of severe depression (10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) F32.2/F32.3/F33.2/F33.3 diagnosis) assessed during telephone interview, see table 1.
The exclusion of individuals with severe depression is due to ethical concerns and based on ICD-10 criteria for severe depression according to the German treatment guidelines for depression.33 A trained psychotherapist (HB, LS, EM or SaS) contacts the participant to initiate further actions when severe depression is classified. We invite participants with a depression severity of PHQ ≥5, who do not fulfil the criteria to participate, in a parallel conducted trial for CBP and subclinical depressive symptoms: eSano BackCare-D.34
Procedure on suicidal ideation
Participants who are currently suffering from suicidal ideation are identified by suicide screenings within the telephone interviews (SCID, Hamilton Rating Scale for Depression (HAM-D35), Quick Inventory of Depressive Symptomatology (QIDS36)) and questionnaires (PHQ-9) and potentially through communication with the eCoach or the study administration. Following a suicide protocol adapted from prior trials,37–39 we send an email with detailed information on available health services and the advice to seek professional help if participants report low suicidal ideation (HAM-D, QIDS or PHQ-9 item score=1). In case of moderate-to-high suicidal ideation during the assessments or any suicidal thoughts or intentions reported to an eCoach or the study administration, a trained psychotherapist from the study team (HB, LS, EM or SaS) contacts the participant and initiate further actions. In the case of suicidal ideation communicated to the eCoach, unblinding is regarded as permissible.
eSano BackCare-D is based on cognitive behavioural therapy (CBT), systematic behavioural activation40–42 and problem solving.43 The depression-specific components are based on a prior IMI ‘GET.ON Mood Enhancer’, that has been evaluated in numerous RCTs in different samples37 44 45 and shown to be effective in lowering depressive symptoms in individuals with diabetes mellitus type 1 and 2 with an intention-to-treat (ITT) effect size of d=0.89 at 2 months post-treatment45 and d=0.83 at 6 months follow-up.46 We added CBP-relevant information, videos and audio clips, based on existing literature on psychological back pain treatment,47 48 our clinical experience and an existing IMI for chronic pain individuals based on acceptance and commitment therapy.49 50 Think-aloud interviews with five persons with CBP helped us to pilot validate the intervention and further improve its feasibility and acceptability before recruitment start. Access to the platform proceeds through a unique username password combination and is available on a 24/7 basis from all devices with internet access, however, optimised for PCs, notebooks and (large-screen) tablets. It is not possible to assess which device will be used by individual participants. Additionally, a text message coach is provided in eSano BackCare-D that is described below. All transferred data are secured via www.minddistrict.com based on ISO27001 and guidelines NEN7510.
eSano BackCare-D provides six minimally guided sessions with an estimated proceeding duration of 45–60 min each, developed to be processed weekly. Three optional sessions with back pain-specific topics (sleep, partnership and sexuality, returning to work) are available at the end of sessions 3 through 5. Two booster sessions following the intervention are offered to improve sustainability of intervention effects. Session-specific contents and homework assignments are shown in table 2.
Session 1 provides psychoeducational information on depression, the interaction between CBP and depression as well as pain acceptance. Participants define their depression-related and CBP-related goals and get to know the mood diary as the homework assignment for the next week. In session 2, the concept of behavioural activation and the connection between pleasant activities and mood is introduced. Based on the principles of action planning and coping planning,51 52 participants create an individual list and schedule for completion of pleasant activities in the next few days. The main focus in sessions 3 and 4 is on the six-step plan to handle solvable problems and to better manage emerging issues, comparable to other studies.45 53–55 In addition, techniques to reduce rumination on unsolvable problems and the concept of mindfulness are introduced. Session 5 includes information and exercises on physical activity,42 a mindfulness exercise and techniques to strengthen self-esteem. The sixth session serves to assess intervention-related changes in mood and provides a list of additional treatment options. Participants are encouraged to create a plan for the future. At the end, they write a letter to themselves about specific goals for the next 4 weeks and choose the date of the next booster session (after 2, 4 or 6 weeks) that are developed to review what the participants have learnt in previous sessions and to provide motivation to maintain and expand learnt skills in the future.
The sleep session builds on an evidence-based IMI for insomnia, that is, GET.ON Recovery.56 57 As insomnia is a predictor and symptom of depression,58 participants learn about the principles of sleep hygiene, sleep restriction and stimulus control.59 The partnership and sexuality session provides communication skills and exercises for improving physical closeness and sexuality. In the returning to work session, participants receive information on self-management and interpersonal competences as well as exercises in problem solving and physical relaxation.
Text message coach
The text message coach in eSano BackCare-D automatically sends one supportive text message per day for the duration of 6 weeks as text message prompts have been shown to increase efficacy and adherence of IMIs.60–62 The contents include a) reminders to complete the weekly assignments, b) repetition of the content, and c) motivation enhancement components.
Based on previous studies showing that guidance and reminders and strict deadlines seem to be important with regard to the respective primary outcomes and adherence in IMIs,20 63–65 the feedback manual of eSano BackCare-D provides instructions to remind, set deadlines and formulate standardised feedback for each session. Trained and supervised eCoaches (psychologists) serve as contact person and provide feedback within two work days after each completed session. Feedbacks are adapted to the participants' assignments and include positive reinforcement for completion of assignments and encouragement to proceed with the time spent on guidance will be approximately 60–100 min per participant.
Participants have unrestricted access to TAU. All types of medical/psychological help received during the last 3 months are tracked at T0 and T2 with the Trimbos/iMTA questionnaire for costs associated with mental illness.66
Proposed sample size/power calculations
The sample size calculation is based on the primary endpoint, the HAM-D score at post-treatment. According to the results of trials on online interventions for depression,20 a treatment effect (pooled effect size) of d=0.39 would be of clinical interest and is considered feasible for the type of treatment. On the basis of a two-sample t-test at two-sided significance level of 0.05, the study is planned to detect this effect with 80% power. This requires a sample of 105 individuals in each arm.
Depressive symptoms are assessed by the PHQ-927 which is a well validated depression screening instrument that has also been evaluated to be delivered as online version,67 with a Cronbach’s alpha of 0.89 and 84% sensitivity and 72% specificity for major depression.68
The 17-item HAM-D is the most widely used clinician-rated measure of depression severity and as such viewed as the gold standard for the assessment of depression severity. Additionally, we use the QIDS36, which assesses the severity of depressive symptoms, covering all criterion symptom domains of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) to diagnose a major depressive episode.31 32 Moreover, we use section A (affective syndromes) of the SCID31 as a comprehensive, structured interview designed to be used by trained interviewers for the assessment of mental disorders according to the definitions and criteria of DSM. It enables a reliable, valid and efficient assessment of depressive disorders.32 As an add-on to the SCID for DSM-IV, we use a German translation of the SCID-5-RV to allow for DSM-569 diagnoses as well.
Interviewers are trained and weekly supervised by a psychologist (LS, EM) and are blinded to randomisation condition. At the beginning of each interview, participants and interviewers will be reminded to keep blinding throughout the assessment. After an initial training session, a supervisor and the interviewers assess the same participant together, with comparison of results as follows: the inter-rater reliability (IRR) for the SCID, measured by Cohen’s kappa and the intraclass correlation (ICC) for the HAM-D and QIDS. An almost perfect Cohen’s kappa ≥0.8170 and an excellent ICC coefficient ≥0.7571 is considered as sufficient. Each interviewer is compared with trainers' rating (LS, EM) until the sufficient IRR values are met. Afterwards, the interviewers are compared with each other on a random basis to assess the IRR.
Depression severity is the core patient-relevant outcome in trials among depressed individuals72 73 and is assessed by means of the clinician-rated HAM-D-1735; (see table 1) at post-treatment (T1) as part of the telephone interview. IRR of the SCID was reported to be high for IRR comparing telephone and face-to-face interviews.74
Depression response and remission
HAM-D scores are used to determine depression response in accordance with the recommendations of Jacobson and Truax.75 Depression remission is assessed by means of the SCID as part of the telephone interviews.
Health-related quality of life
The AQoL-6D includes 20 items and 6 dimensions and is suitable for quality of life assessments and economic evaluations of health programme with good psychometric properties76 and α=0.89.77 We additionally obtain the most widely used quality of life assessment EuroQol (EQ-5D-5L) as a basis for cost-utility analyses (CUA) with five health domains of importance to quality of life.78
We use an 11-point numerical rating (0–10) of the worst, least and average pain during the last week and calculate the mean of the three scales. Additionally, we use a categorical rating of pain intensity (none, mild, moderate, severe).
The Pain Self-Efficacy Questionnaire (PSEQ) is a validated and reliable (internal consistency: α=0.93) 10-item instrument that assesses self-efficacy expectations related to pain.81
The Subjective Prognostic Employment Scale is a validated 3-item self-report questionnaire (sum score 0–3) with high internal consistency (rep (Guttman scaling)=0.9982).
The attrition rate (calculated using the percentage of individuals who no longer use the intervention, as assessed by their log in data) gives an estimate of the individuals’ intervention adherence.
The Client Satisfaction Questionnaire (CSQ-8; German: ZUF-8), optimised for the assessment of client satisfaction in IMIs (CSQ-8)83 84 is a validated eight-item instrument with high internal consistency (α=0.92).84 The adapted version for the assessment of client satisfaction in IMIs has shown to have high internal consistency in a range of studies (α=0.92–0.94)57 85 86 and to be associated with treatment adherence and outcome.
Negative effects of psychotherapy
We include different ways of monitoring serious adverse events (SAE) adapted from the National Institute for Health Research recommendations87 and Horigian et al,88 who give general principles and examples to help illustrate their definition of SAEs: participants' responses in interviews, reported SAEs to the eCoach and SAEs assessed by means of the Inventory for the Assessment of Negative Effects of Psychotherapy (INEP) during the online assessments.89 The INEP consists of 15 items assessing a range of common changes participants experienced in line with the intervention. Cronbach’s alpha is α=0.86.89 At the beginning of every session, participants are asked about adverse events and are also encouraged to report the events to their eCoach who monitors the SAEs and initiates further actions if needed.
We use the German version of the Cost Questionnaire ‘Trimbos Institute and Institute of Medical Technology Questionnaire for Costs Associated with Psychiatric Illness’ (TiC-P; 59), adapted for the German healthcare system by Nobis et al 39 and for CBP individuals by the present authors. The TiC-P allows assessment of all direct healthcare services received during the last 3 months. Moreover, direct non-medical costs (eg, travel costs) and indirect costs are assessed, including the number of ‘work loss’ days (absenteeism), the number of ‘work cut-back’ days (presentism) and costs associated with domestic tasks.
Demographic variables, prior depression treatments and internet affinity level are assessed by patient self-report, see table 1. We use the German version of the Internet Affinity Scale by Haase et al 90 to assess familiarity with the internet. Depression type (major depression yes/no), baseline severity and depression chronicity are assessed by the SCID, back pain type, severity and chronicity are extracted from medical records.
The primary outcome will be analysed with the HAM-D score at T1 as dependent variable and baseline value as covariates, adjusting for sex and age. Continuous secondary outcomes will be analysed accordingly. Standardised mean differences and 95% CIs will be calculated to measure the between-group effect size at post-treatment and follow-up. Additionally, clinical significance analyses, such as number needed to treat will be conducted. All analyses will be performed on an ITT principle with multiple imputations to replace missing data.91 Completer analyses (per-protocol) will be conducted to investigate the influence of study attrition on study results. Rates of patient-reported adverse events will be compared.
We will conduct a cost-effectiveness analysis (CEA) and a CUA. Outcome estimates will be the incremental cost-effectiveness ratio (ICER) and the incremental cost-utility ratio (ICUR) after 6 months. A CEA with depression response as clinical outcome will be conducted. The generic outcome for the CUA will be quality-adjusted life-years (QALYs), which will be based on the AQoL-6D76 and in a sensitivity analysis based on the EQ-5D-5L.78 Both analyses will be conducted from a societal perspective including all direct and indirect costs. Non-parametric bootstrapping will be used to take into account stochastic uncertainty of the ICER. Furthermore, we will calculate a cost-acceptability curve to test the likelihood that the intervention is cost-effective relative to TAU, given varying threshold for the willingness to pay for one depression response or QALY gained, respectively.
Ethics and dissemination
All procedures are approved by the ethics committee of the Albert-Ludwigs-University of Freiburg and the data security committee of the German Pension Insurance (Deutsche Rentenversicherung). The trial has been registered prior to recruitment start at the WHO International Clinical Trials Registry Platform via the German Clinical Studies Trial Register (DRKS): (DRKS00009272).
We conduct and report the RCT in accordance with the CONSORT 2010 Statement,92 the supplement of the CONSORT statement for pragmatic effectiveness trials92 93 and current guidelines for executing and reporting internet intervention research 28 94. The results will be published in peer-reviewed journals and presented on international conferences.
Quality assurance and safety
The Clinical Trials Unit Freiburg performs monitoring visits to the participating clinic centres before, during and after completion of the study to ensure that the study is conducted, recorded and reported according to the study protocol, relevant standard operating procedures and requirements of the sponsor and/or the Ethic Committees in accordance with the Good Clinical Practice of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH -GCP, http://ichgcp.net/). Rigorous operating procedures for data management and safety have been implemented. The principal investigator and the research assistants have access to the source data that will be kept for as long as the study takes until 10 years after completion.
Furthermore, an independent Data Safety and Monitoring Board (DSMB) consisting of two experienced scientists and psychotherapists (MHä, MHa) and one statistician (LK) with long-standing experience in clinical trials has been established. The function of the DSMB is to monitor the course of the study and, if necessary, to give recommendations to the steering committee for discontinuation, modification or continuation of the study.
The present effectiveness and cost-effectiveness trial focusses on individuals with CBP and comorbid depression as two of the most frequent, most disabling health conditions with high associated economic burden.5 94
The WARD-BP trial is innovative in several ways: (a) studies examining the effectiveness of psychological depression interventions are regularly methodologically limited as they lack diagnostic clarification of depression status.20 73 93 By carrying out the SCID and HAM-D prior to randomisation and at follow-up assessments, the present trial will be the first trial on a psychological depression intervention for people with chronic pain with verified DSM diagnosis of depression; (b) with a target sample of 210 participants, the study will be optimally powered, overcoming limitations of small scale trials on psychological depression interventions in the medically ill12 73 93; (c) the eSano BackCare-D intervention is tailored to the special needs of the target group of patients with CBP. This has been discussed to have an uptake and adherence facilitating effect,95 likely to improve the effectiveness of online interventions; (d) the implementation of the intervention into the healthcare system overcomes one of the main criticisms regarding IMI trial being only representative for a selective online population96 97; (e) the current trial design will allow examination of the reach of this IMI and will provide valuable information about which CBP individuals are willing to use such interventions. With the use of two different recruitment strategies, we will be able to compare two different ways of implementing IMIs into clinical routine. This will allow for conclusions on feasible ways of improving the adherence and uptake of IMIs in respective target populations98–100; (f) finally, as one of still few clinical trials on psychological depression interventions the present trial comprises a CEA.
If the results of WARD-BP indicate that eSano BackCare-D is effective and cost-effective, its clinical impact on depression healthcare services could be substantial. When implemented as part of the standard healthcare, IMIs have the potential to reduce the ‘lost in transition phenomenon’ caused by fragmented healthcare systems.26 101 102 Engaging individuals in treatment at the interface of different healthcare sectors, as in the present (cost-)effectiveness trial, will contribute important information on potential approaches to improve the delivery of mental healthcare and at the same time provide insights on possible ways of implementing depression IMIs into care for CPB in order to exploit their full potential. The first results of WARD-BP are expected in 2018.
The authors thank Dr Kristin Kieselbach and Professor Dr Anja Göritz for their support with providing their expertise in the content of the intervention. The authors thank colleagues who were part of the development of prior interventions that partly build the basis of eSano BackCare-D. Moreover, the authors like to thank our study assistants and interns and students for their support in the development of the intervention and in conducting the study. The authors thank Ellen Meierotto for supervising the SCID interviewers. Many thanks go to the Data Safety and Monitoring Board, consisting of Professor Dr Martin Hautzinger, Professor Dr Martin Härter and Dr Levente Kriston as well as the Clinical Trials Unit Freiburg for their support in carrying out the study project. Special thanks go to the eight orthopaedic clinics Schoen Klinik, Bad Staffelstein; RehaklinikSonnhalde, Donaueschingen; RehaKlinikum Bad Säckingen; Städt. Rehakliniken Bad Wald-see; Schwarzwaldklinik Orthopädie - Abteilung Medizinische Rehabilitation, Bad Krozingen; Rheintalklinik Bad Krozingen; REGIO-Reha Tagesklinik, Freiburg and Universitäts- und Rehabilitationskliniken, Ulm as well as the further orthopaedic rehabilitation units of the second recruitment strategy. The authors are very grateful to Mary Wyman for proofreading and language editing of this manuscript.
Contributors HB, DE, MB, OM and HR initiated this study. All authors contributed to the design of this study. HB, LS, SP, DE, SaS, DL, SN, JB, HR, MB and JL developed the intervention content eSano BackCare-D is based on as well as the assessment. HB, LS, SP, SaS, DE and JL are responsible for recruitment. SaS is responsible for randomisation and allocation as well as the administration of participants. JL wrote the draft of the manuscript. HB provided expertise on depression, CBP and psychological pain interventions. All authors contributed to the further writing of the manuscript and approved the final version of the manuscript.
Funding This study is funded by the Federal Ministry of Education and Research of Germany (project: effectiveness of a guided web-based intervention for depression in back pain rehabilitation aftercare, grant number: 01GY1330A). This funding source has no influence on the design of this study and will not influence its execution, analyses, interpretation of the data or decision to submit results.
Competing interests JL, LS, SP, SS, JB, SN, OM, HR and HB report no conflict of interest. DE, MB and DL are stakeholders of the ’Institute for Online Health Trainings', a company aiming to transfer scientific knowledge related to the present research into routine healthcare. A committee of independent scientists has been formed (Data Safety and Monitoring Board (DSMB)) to supervise study-related decisions and prevent any influence of a potential conflict of interest.
Ethics approval Ethics committee of the Albert- Ludwigs-University of Freiburg.
Provenance and peer review Not commissioned; externally peer reviewed.